• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors.巯基乙酰胺组蛋白去乙酰化酶抑制剂的体外血浆稳定性、通透性和溶解性
Int J Pharm. 2008 Sep 1;361(1-2):19-25. doi: 10.1016/j.ijpharm.2008.05.001. Epub 2008 May 13.
2
Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors.基于巯基乙酰胺的组蛋白去乙酰化酶抑制剂的药代动力学-药效学和抗肿瘤活性。
Mol Cancer Ther. 2009 Oct;8(10):2844-51. doi: 10.1158/1535-7163.MCT-09-0629. Epub 2009 Sep 29.
3
In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.新型组蛋白去乙酰化酶抑制剂SB639在临床前物种中的体外I期细胞色素P450代谢、通透性及药代动力学
Biol Pharm Bull. 2007 May;30(5):1021-4. doi: 10.1248/bpb.30.1021.
4
Iron complexation to histone deacetylase inhibitors SAHA and LAQ824 in PEGylated liposomes can considerably improve pharmacokinetics in rats.在聚乙二醇化脂质体中,铁与组蛋白脱乙酰酶抑制剂SAHA和LAQ824络合可显著改善大鼠体内的药代动力学。
J Pharm Pharm Sci. 2014;17(4):583-602. doi: 10.18433/j3ts4v.
5
Involvement of P-glycoprotein and multidrug resistance associated protein 1 on the transepithelial transport of a mercaptoacetamide-based histone-deacetylase inhibitor in Caco-2 cells.P-糖蛋白和多药耐药相关蛋白1在巯基乙酰胺基组蛋白去乙酰化酶抑制剂经Caco-2细胞跨上皮转运中的作用
Biol Pharm Bull. 2009 Jan;32(1):74-8. doi: 10.1248/bpb.32.74.
6
Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.一种新型基于苯丁酸盐的组蛋白去乙酰化酶抑制剂(S)-HDAC-42对前列腺癌的抗肿瘤作用
Clin Cancer Res. 2006 Sep 1;12(17):5199-206. doi: 10.1158/1078-0432.CCR-06-0429.
7
Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.发现并广泛评估 NK-HDAC-1:一种手性组蛋白去乙酰化酶抑制剂作为有前途的先导物。
J Med Chem. 2012 Apr 12;55(7):3066-75. doi: 10.1021/jm201496g. Epub 2012 Mar 30.
8
SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.SB939,一种新型有效的组蛋白去乙酰化酶抑制剂,具有高肿瘤暴露量和在结直肠癌小鼠模型中的疗效。
Mol Cancer Ther. 2010 Mar;9(3):642-52. doi: 10.1158/1535-7163.MCT-09-0689. Epub 2010 Mar 2.
9
Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.组蛋白去乙酰化酶抑制剂的结构要求:基于异羟肟酸修饰的SAHA类似物
Arch Pharm (Weinheim). 2016 May;349(5):373-82. doi: 10.1002/ardp.201500472. Epub 2016 Apr 9.
10
Preclinical studies of YK-4-272, an inhibitor of class II histone deacetylases by disruption of nucleocytoplasmic shuttling.通过破坏核质穿梭来抑制 II 类组蛋白去乙酰化酶的 YK-4-272 的临床前研究。
Pharm Res. 2012 Dec;29(12):3373-83. doi: 10.1007/s11095-012-0832-3. Epub 2012 Jul 27.

引用本文的文献

1
Preclinical pharmacokinetics and in vitro ADME properties of PAT-1102: a novel HDAC inhibitor for cancer therapy.PAT-1102的临床前药代动力学及体外吸收、分布、代谢和排泄特性:一种用于癌症治疗的新型组蛋白去乙酰化酶抑制剂
J Cancer Res Clin Oncol. 2025 May 24;151(5):174. doi: 10.1007/s00432-025-06227-5.
2
Multiparameter ranking of carbazoles for anti-trypanosome lead discovery.用于抗锥虫先导化合物发现的咔唑类化合物的多参数排名
Front Drug Discov (Lausanne). 2024;4. doi: 10.3389/fddsv.2024.1430927. Epub 2024 Aug 14.
3
The marine xanthophyll diatoxanthin as ferroptosis inducer in MDAMB231 breast cancer cells.海洋叶黄素二异岩藻黄素作为MDAMB231乳腺癌细胞中铁死亡的诱导剂。
Sci Rep. 2025 Mar 9;15(1):8146. doi: 10.1038/s41598-025-91519-6.
4
Pharmacophore Identification and Structure-Activity Relationship Analysis of a Series of Substituted Azaindoles as Inhibitors of .取代氮茚类化合物作为. 抑制剂的药效团识别和构效关系分析
J Med Chem. 2024 Aug 22;67(16):13985-14006. doi: 10.1021/acs.jmedchem.4c00785. Epub 2024 Aug 13.
5
Pharmacokinetics of Panobinostat: Interspecies Difference in Metabolic Stability.帕比司他的药代动力学:种间代谢稳定性差异
J Pharmacol Exp Ther. 2024 Mar 15;389(1):96-105. doi: 10.1124/jpet.123.002051.
6
Pharmacokinetic Profile Evaluation of Novel Combretastatin Derivative, LASSBio-1920, as a Promising Colorectal Anticancer Agent.新型柯里拉京衍生物LASSBio-1920作为一种有前景的结直肠癌抗癌药物的药代动力学特征评估。
Pharmaceutics. 2023 Apr 19;15(4):1282. doi: 10.3390/pharmaceutics15041282.
7
2-Arylpropionic Acid Pyrazolamides as Cannabinoid CB2 Receptor Inverse Agonists Endowed with Anti-Inflammatory Properties.2-芳基丙酸吡唑酰胺作为具有抗炎特性的大麻素CB2受体反向激动剂
Pharmaceuticals (Basel). 2022 Dec 6;15(12):1519. doi: 10.3390/ph15121519.
8
Cationic Perylene Antivirals with Aqueous Solubility for Studies In Vivo.具有水溶性的用于体内研究的阳离子苝类抗病毒剂。
Pharmaceuticals (Basel). 2022 Sep 22;15(10):1178. doi: 10.3390/ph15101178.
9
Development of an LC-MS/MS Method for ARV-110, a PROTAC Molecule, and Applications to Pharmacokinetic Studies.建立一种用于 ARV-110(一种 PROTAC 分子)的 LC-MS/MS 方法及其在药代动力学研究中的应用。
Molecules. 2022 Mar 18;27(6):1977. doi: 10.3390/molecules27061977.
10
Acute toxicity analysis of an inhibitor of BCL2, Disarib, in rats.Disarib 一种 BCL2 抑制剂的大鼠急性毒性分析。
Sci Rep. 2021 May 11;11(1):9982. doi: 10.1038/s41598-021-89387-x.

本文引用的文献

1
Comparative plasma pharmacokinetics of meloxicam in sheep and goats following intravenous administration.美洛昔康静脉注射后在绵羊和山羊体内的血浆药代动力学比较
Comp Biochem Physiol C Toxicol Pharmacol. 2007 May;145(4):528-32. doi: 10.1016/j.cbpc.2007.01.020. Epub 2007 Feb 22.
2
The paradox of histone deacetylase inhibitor-mediated modulation of cellular responses to radiation.组蛋白去乙酰化酶抑制剂介导的细胞对辐射反应调节的悖论。
Cell Cycle. 2006 Feb;5(3):288-95. doi: 10.4161/cc.5.3.2421. Epub 2006 Feb 17.
3
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.组蛋白去乙酰化酶抑制剂与癌症表观遗传(及更多方面)治疗的前景。
Nat Rev Cancer. 2006 Jan;6(1):38-51. doi: 10.1038/nrc1779.
4
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.口服组蛋白去乙酰化酶抑制剂伏立诺他治疗晚期癌症患者的I期研究
J Clin Oncol. 2005 Jun 10;23(17):3923-31. doi: 10.1200/JCO.2005.14.167. Epub 2005 May 16.
5
Correlation of in vitro cytotoxicity with paracellular permeability in Caco-2 cells.Caco-2细胞中体外细胞毒性与细胞旁通透性的相关性。
Toxicol In Vitro. 2005 Aug;19(5):675-84. doi: 10.1016/j.tiv.2005.03.006.
6
Development and application of high throughput plasma stability assay for drug discovery.用于药物发现的高通量血浆稳定性测定方法的开发与应用。
Int J Pharm. 2005 Jun 13;297(1-2):110-9. doi: 10.1016/j.ijpharm.2005.03.022.
7
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.组蛋白去乙酰化酶抑制剂MS - 275在晚期难治性实体瘤或淋巴瘤患者中的I期及药代动力学研究。
J Clin Oncol. 2005 Jun 10;23(17):3912-22. doi: 10.1200/JCO.2005.02.188. Epub 2005 Apr 25.
8
Molecular properties of WHO essential drugs and provisional biopharmaceutical classification.世界卫生组织基本药物的分子特性及临时生物药剂学分类
Mol Pharm. 2004 Jan 12;1(1):85-96. doi: 10.1021/mp034006h.
9
Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors.基于巯基酰胺的非异羟肟酸型组蛋白去乙酰化酶抑制剂。
Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. doi: 10.1016/j.bmcl.2005.02.075.
10
Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors.巯基乙酰胺作为新型组蛋白去乙酰化酶抑制剂的化学与生物学特性
Bioorg Med Chem Lett. 2005 Mar 1;15(5):1389-92. doi: 10.1016/j.bmcl.2005.01.006.

巯基乙酰胺组蛋白去乙酰化酶抑制剂的体外血浆稳定性、通透性和溶解性

In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors.

作者信息

Konsoula Roula, Jung Mira

机构信息

Department of Radiation Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.

出版信息

Int J Pharm. 2008 Sep 1;361(1-2):19-25. doi: 10.1016/j.ijpharm.2008.05.001. Epub 2008 May 13.

DOI:10.1016/j.ijpharm.2008.05.001
PMID:18562136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2565275/
Abstract

Histone deacetylase inhibitors (HDACIs) are emerging as a new class of therapeutic agents with potent antitumor activities in a broad spectrum of human cancers. In this study, the in vitro plasma stability, permeability, solubility, and lipophilicity (log D) of two mercaptoacetamide-based HDACIs (coded as W2 and S2) were evaluated and compared to Vorinostat (SAHA). The results demonstrated that the compounds manifested high solubility in HCl (pH 1.2) but lower in PBS (pH 7.4) than SAHA. Moreover, mercaptoacetamide-based HDACIs exhibited higher lipophilicity values compared to SAHA. The permeability of these compounds was evaluated using the Caco-2 cell monolayer as a model of the intestinal mucosa. The Caco-2 studies revealed that the compounds S2 and W2 are highly permeable with apparent permeability coefficients (P(app)) in the apical to basolateral direction of 7.33 x 10(-6) and 15.0 x 10(-6)cm/s, respectively. The in vitro stability was determined in human, mouse, porcine and rat plasma. Data showed that the compound W2 is more stable in human and rat plasma and the S2 is more stable in all plasma species than SAHA. Taken together, these results indicate that the mercaptoacetamide-based HDACIs possess favorable solubility, lipophilicity, permeability and plasma stability features.

摘要

组蛋白去乙酰化酶抑制剂(HDACIs)正在成为一类新型治疗药物,在多种人类癌症中具有强大的抗肿瘤活性。在本研究中,评估了两种基于巯基乙酰胺的HDACIs(编码为W2和S2)的体外血浆稳定性、通透性、溶解度和亲脂性(log D),并与伏立诺他(SAHA)进行了比较。结果表明,这些化合物在HCl(pH 1.2)中表现出高溶解度,但在PBS(pH 7.4)中的溶解度低于SAHA。此外,与SAHA相比,基于巯基乙酰胺的HDACIs表现出更高的亲脂性值。使用Caco-2细胞单层作为肠黏膜模型评估了这些化合物的通透性。Caco-2研究表明,化合物S2和W2具有高通透性,其从顶端到基底外侧方向的表观通透系数(P(app))分别为7.33×10(-6)和15.0×10(-6)cm/s。在人、小鼠、猪和大鼠血浆中测定了体外稳定性。数据显示,化合物W2在人血浆和大鼠血浆中更稳定,而S2在所有血浆种类中都比SAHA更稳定。综上所述,这些结果表明基于巯基乙酰胺的HDACIs具有良好的溶解度、亲脂性、通透性和血浆稳定性特征。